The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InCan-Fite BioPharma Ltd. (NYSE American: CANF) has announced successful results from its Phase 2a clinical trial evaluating Namodenoson for advanced pancreatic cancer. The study achieved its primary endpoint, demonstrating the drug's efficacy in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants in the trial had previously progressed following other systemic therapies, making this a significant milestone for difficult-to-treat cases. Namodenoson is a small molecule drug designed to target specific receptors in cancer cells while maintaining a favorable safety profile. The company's shares, which trade on both the NYSE American and the Tel Aviv Stock Exchange, are expected to see increased investor interest following this clinical breakthrough. This development marks a critical step forward in Can-Fite's oncology pipeline and its efforts to address unmet medical needs in the cancer treatment landscape.